Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
13 "Jihye Cha"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Lung and Thoracic cancer
Upfront Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients with Brain Metastases from Non–Small Cell Lung Cancer: A Retrospective Analysis of a 10-Year Bi-institutional Experience
Myungsoo Kim, Jihye Cha, Hun Jung Kim, Woo Chul Kim, Jeongshim Lee
Cancer Res Treat. 2025;57(1):47-56.   Published online July 3, 2024
DOI: https://doi.org/10.4143/crt.2024.223
AbstractAbstract PDFPubReaderePub
Purpose
Stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) are increasingly used as initial therapies for brain metastases (BM). We aimed to assess the outcomes of SRS/FSRT in patients aged ≥ 65 years who had 1-10 BM from non–small cell lung cancer (NSCLC).
Materials and Methods
We retrospectively reviewed 91 elderly NSCLC patients with 222 BM who were treated with SRS/FSRT at two institutions between 2010 and 2020. The primary endpoint was overall survival (OS) after SRS/FSRT. In addition, in-field local control (IFLC) within the treated field was evaluated. Statistical analysis was performed to identify the prognostic factors affecting OS and IFLC.
Results
During a median follow-up of 18 months, the median OS was 32 months. The 1- and 2-year survival rates were 69.8% and 56.1%, respectively. In multivariate analysis, the NSCLC-specific graded prognostic assessment (GPA) score (p=0.007) and administration of systemic therapy (p=0.039) were defined as prognosticators affecting OS. The median IFLC period was 31 months, and the 1- and 2-year IFLC rates were 75.9% and 57.6%, respectively. The total BM volume (p=0.042) significantly affected IFLC. No severe adverse events were reported after SRS/FSRT.
Conclusion
SRS/FSRT is an effective upfront treatment option for BM arising from NSCLC in elderly patients, with a good OS without severe side effects. Higher GPA score and active systemic treatment were associated with improved OS, indicating that elderly patients are significant candidates for SRS/FSRT.
  • 2,080 View
  • 176 Download
Close layer
Breast cancer
The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129.   Published online December 31, 2021
DOI: https://doi.org/10.4143/crt.2021.1083
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by  
  • Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
    Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
    Breast Cancer Research and Treatment.2023; 200(1): 37.     CrossRef
  • 6,748 View
  • 186 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Postmastectomy Radiation Therapy for Node-Negative Breast Cancer of 5 cm or Larger Tumors: A Multicenter Retrospective Analysis (KROG 20-03)
Kyubo Kim, Jinhong Jung, Haeyoung Kim, Wonguen Jung, Kyung Hwan Shin, Ji Hyun Chang, Su Ssan Kim, Won Park, Jee Suk Chang, Yong Bae Kim, Sung Ja Ahn, Ik Jae Lee, Jong Hoon Lee, Hae Jin Park, Jihye Cha, Juree Kim, Jin Hwa Choi, Taeryool Koo, Jeanny Kwon, Jin Hee Kim, Mi Young Kim, Shin-Hyung Park, Yeon-Joo Kim
Cancer Res Treat. 2022;54(2):497-504.   Published online August 25, 2021
DOI: https://doi.org/10.4143/crt.2021.933
AbstractAbstract PDFPubReaderePub
Purpose
To evaluate the role of postmastectomy radiation therapy (PMRT) in patients with node-negative breast cancer of 5cm or larger tumors undergoing mastectomy
Materials and Methods
Medical records of 274 patients from 18 institutions treated with mastectomy between January 2000 and December 2016 were retrospectively reviewed. Among these, 202 patients underwent PMRT, while 72 did not. Two hundred and forty-one patients (88.0%) received systemic chemotherapy, and 172 (62.8%) received hormonal therapy. Patients receiving PMRT were younger, more likely to have progesterone receptor-positive tumors, and received adjuvant chemotherapy more frequently compared with those without PMRT (p <0.001, 0.018, and <0.001, respectively). Other characteristics were not significantly different between the two groups.
Results
With a median follow-up of 95 months (range, 1-249), there were 9 locoregional recurrences, and 20 distant metastases. The 8-year locoregional recurrence-free survival rates were 98.0% with PMRT and 91.3% without PMRT (p=0.133), and the 8-year disease-free survival (DFS) rates were 91.8% with PMRT and 73.9% without PMRT (p=0.008). On multivariate analysis incorporating age, histologic grade, lymphovascular invasion, hormonal therapy, chemotherapy, and PMRT, the absence of lymphovascular invasion and the receipt of PMRT were associated with improved DFS (p=0.025 and 0.009, respectively).
Conclusion
Locoregional recurrence rate was very low in node-negative breast cancer of 5cm or larger tumors treated with mastectomy regardless of the receipt of PMRT. However, PMRT was significantly associated with improved DFS. Further investigation is needed to confirm these findings.

Citations

Citations to this article as recorded by  
  • Outcomes with and without postmastectomy radiotherapy for pT3N0‐1M0 breast cancer: An institutional experience
    Xinxin Rao, Xuanyi Wang, Kairui Jin, Yilan Yang, Xu Zhao, Zhe Pan, Weiluo Lv, Zhen Zhang, Li Zhang, Xiaoli Yu, Xiaomao Guo
    Cancer Medicine.2024;[Epub]     CrossRef
  • The effect of radiotherapy on patients with pathological stage IIB breast cancer after breast-conserving surgery or mastectomy: A cohort study
    Yi-Ying Pan, Tzu-Yu Lai, Cheng-Ying Shiau, Ling-Ming Tseng, I-Chun Lai, Yu-Ming Liu, Pin-I Huang
    Journal of the Chinese Medical Association.2024; 87(2): 202.     CrossRef
  • Post-mastectomy radiation therapy after breast reconstruction: from historic dogmas to practical expert agreements based on a large literature review of surgical and radiation therapy considerations
    Yazid Belkacemi, Meena S. Moran, Burcu Celet Ozden, Yazan Masannat, Fady Geara, Mohamed Albashir, Nhu Hanh To, Kamel Debbi, Mahmoud El Tamer
    Critical Reviews in Oncology/Hematology.2024; 200: 104421.     CrossRef
  • Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer
    Ke Liu, Jia-Yi Li, Guan-Qiao Li, Zhen-Yu He, San-Gang Wu
    Expert Review of Anticancer Therapy.2024; 24(12): 1283.     CrossRef
  • Post-Mastectomy Radiation Therapy: Applications and Advancements
    Jessica L. Thompson, Steven G. Allen, Cecilia Pesavento, Corey W. Speers, Jacqueline S. Jeruss
    Current Breast Cancer Reports.2022; 14(3): 75.     CrossRef
  • 7,568 View
  • 206 Download
  • 5 Crossref
Close layer
Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROG 19-02)
Yeon Joo Kim, Yeon-Joo Kim, Yong Bae Kim, Ik Jae Lee, Jeanny Kwon, Kyubo Kim, Jihye Cha, Myungsoo Kim, In Young Jo, Jung Hoon Kim, Jaehyeon Park, Jin Hee Kim, Juree Kim, Kyung Hwan Shin, Su Ssan Kim
Cancer Res Treat. 2022;54(2):478-487.   Published online July 12, 2021
DOI: https://doi.org/10.4143/crt.2021.632
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to investigate the impact of postoperative radiotherapy (PORT) in de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor resection (PTR) and to identify the subgroup of patients who would most benefit from PORT.
Materials and Methods
This study enrolled 426 patients with dnMBC administered PTR alone or with PORT. The primary and secondary outcomes were overall and progression-free survival (OS and PFS), respectively.
Results
The median follow-up time was 53.7 months (range, 3.1 to 194.4). The 5-year OS and PFS rates were 73.2% and 32.0%, respectively. For OS, clinical T3/4 category, triple-negative breast cancer (TNBC), postoperative chemotherapy alone were significantly poor prognostic factors, and administration of PORT failed to show its significance. Regarding PFS, PORT was a favorable prognostic factor (hazard ratio, 0.64; 95% confidence interval, 0.50 to 0.82; p < 0.001), in addition to T1/2 category, ≤ 5 metastases, and non-TNBC. According to the multivariate analyses of OS in the PORT group, we divided the patients into three groups (group 1, T1/2 and non-TNBC [n=193]; group 2, T3/4 and non-TNBC [n=171]; and group 3, TNBC [n=49]), and evaluated the effect of PORT. Although PORT had no significance for OS in all subgroups, it was a significant factor for good prognosis regarding PFS in groups 1 and 2, not in group 3.
Conclusion
PORT was associated with a significantly better PFS in patients with dnMBC who underwent PTR. Patients with clinical T1/2 category and non-TNBC benefited most from PORT, while those with TNBC showed little benefit.

Citations

Citations to this article as recorded by  
  • Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study
    Pingchuan Li, Lineng Wei, Yinan Ji, Huawei Yang
    Technology in Cancer Research & Treatment.2025;[Epub]     CrossRef
  • Letter to the editor for the article“Tumor margin irregularity degree is an important preoperative predictor of adverse pathology for clinical T1/2 renal cell carcinoma and the construction of predictive model”
    Yaping Miao, Lexin Wang, Ping Chen, Jiaan Lu, Guanhu Yang, Hao Chi
    World Journal of Urology.2024;[Epub]     CrossRef
  • The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
    Tian Yang, Xiaorong Zhong, Jun Wang, Zhongzheng Xiang, Yuanyuan Zeng, Siting Yu, Zelei Dai, Ningyue Xu, Ting Luo, Lei Liu
    Cancer Medicine.2023; 12(7): 8112.     CrossRef
  • Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
    Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
    Radiation Oncology.2023;[Epub]     CrossRef
  • Machine learning predicts the prognosis of breast cancer patients with initial bone metastases
    Chaofan Li, Mengjie Liu, Jia Li, Weiwei Wang, Cong Feng, Yifan Cai, Fei Wu, Xixi Zhao, Chong Du, Yinbin Zhang, Yusheng Wang, Shuqun Zhang, Jingkun Qu
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Factors Influencing Prognosis in Patients with De Novo Stage IV Breast Cancer: A Systematic Review and Meta-Analysis
    Meilin Zhang, Zining Jin, Yingying Xu, Bo Chen, Jian Song, Muyao Li, Feng Jin, Ang Zheng
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • 7,702 View
  • 175 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Impact of Regional Nodal Irradiation for Breast Cancer Patients with Supraclavicular and/or Internal Mammary Lymph Node Involvement: A Multicenter, Retrospective Study (KROG 16-14)
Kyubo Kim, Yuri Jeong, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Chang-Ok Suh, Yong Bae Kim, Doo Ho Choi, Won Park, Jihye Cha, Mison Chun, Dong Soo Lee, Sun Young Lee, Jin Hee Kim, Hae Jin Park, Wonguen Jung
Cancer Res Treat. 2019;51(4):1500-1508.   Published online March 15, 2019
DOI: https://doi.org/10.4143/crt.2018.575
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the treatment outcomes of radiotherapy (RT) for breast cancer with ipsilateral supraclavicular (SCL) and/or internal mammary (IMN) lymph node involvement.
Materials and Methods
A total of 353 patients from 11 institutions were included. One hundred and thirty-six patients had SCL involvement, 148 had IMN involvement, and 69 had both. All patients received neoadjuvant systemic therapy followed by breast-conserving surgery or mastectomy, and postoperative RT to whole breast/chest wall. As for regional lymph node irradiation, SCL RT was given to 344 patients, and IMN RT to 236 patients. The median RT dose was 50.4 Gy.
Results
The median follow-up duration was 61 months (range, 7 to 173 months). In-field progression was present in SCL (n=20) and/or IMN (n=7). The 5-year disease-free survival (DFS) and overall survival rates were 57.8% and 75.1%, respectively. On multivariate analysis, both SCL/IMN involvement, number of axillary lymph node ≥ 4, triple-negative subtype, and mastectomy were significant adverse prognosticators for DFS (p=0.022, p=0.001, p=0.001, and p=0.004, respectively). Regarding the impact of regional nodal irradiation, SCL RT dose ≥ 54 Gy was not associated with DFS (5-year rate, 52.9% vs. 50.9%; p=0.696) in SCL-involved patients, and the receipt of IMN RT was not associated with DFS (5-year rate, 56.1% vs. 78.1%; p=0.099) in IMN-involved patients.
Conclusion
Neoadjuvant chemotherapy followed by surgery and postoperative RT achieved an acceptable in-field regional control rate in patients with SCL and/or IMN involvement. However, a higher RT dose to SCL or IMN RT was not associated with the improved DFS in these patients.

Citations

Citations to this article as recorded by  
  • Clinical outcomes after post-operative radiotherapy for breast cancer patients presenting with ipsilateral supraclavicular metastasis: considerations on the cranial border of irradiation field
    Xiaofang Wang, Xiaomeng Zhang, Li Zhang, Jin Meng, Wei Shi, Xingxing Chen, Zhaozhi Yang, Xin Mei, Xiaoli Yu, Zhen Zhang, Zhimin Shao, Xiaomao Guo, Jinli Ma
    Breast Cancer.2025; 32(1): 144.     CrossRef
  • Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
    Julia M. Selfridge, Zachary Schrank, Chris B. Agala, David W. Ollila, Kristalyn K. Gallagher, Dana L. Casey, Philip M. Spanheimer
    Annals of Surgical Oncology.2025; 32(3): 2070.     CrossRef
  • Internal mammary regional management after neoadjuvant therapy in breast cancer
    Zhao Bi, Chun-Hui Zheng, Tong-Yue Ren, Yong-Sheng Wang
    International Journal of Surgery.2024;[Epub]     CrossRef
  • Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy
    Hyunki Park, Haeyoung Kim, Won Park, Won Kyung Cho, Nalee Kim, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu
    Radiation Oncology Journal.2024; 42(3): 210.     CrossRef
  • Clinical audit of breast cancer patients treated with helical tomotherapy for irradiation of the internal mammary chain
    Garima Shrivastav, Debanjali Datta, Tabassum Wadasadawala, Pallavi Rane, Subhajit Panda, Rima Pathak, Libin Scaria, Revathy Krishnamurthy, Rajiv Sarin
    Journal of Radiotherapy in Practice.2023;[Epub]     CrossRef
  • The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
    Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement
    Kevin Diao, Lauren M. Andring, Carlos H. Barcenas, Puneet Singh, Huong (Carisa) Le-Petross, Valerie K. Reed, Jay P. Reddy, Elizabeth S. Bloom, Neelofur R. Ahmad, Lauren L. Mayo, George H. Perkins, Melissa P. Mitchell, Kevin T. Nead, Welela Tereffe, Benjam
    International Journal of Radiation Oncology*Biology*Physics.2022; 112(1): 66.     CrossRef
  • Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement
    Lauren M. Andring, Kevin Diao, Susie Sun, Miral Patel, Gary J. Whitman, Pamela Schlembach, Isadora Arzu, Melissa M. Joyner, Simona F. Shaitelman, Karen Hoffman, Michael C. Stauder, Benjamin D. Smith, Wendy A. Woodward
    International Journal of Radiation Oncology*Biology*Physics.2022; 113(3): 552.     CrossRef
  • Yesterday, Today and Tomorrow – Are We Any Closer to Knowing Which Patients Will Benefit from Adjuvant Internal Mammary Nodal Irradiation?
    C.A. Johnson, J. Evans
    Clinical Oncology.2022; 34(8): 534.     CrossRef
  • Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study
    Haeyoung Kim, Yeon Jeong Kim, Donghyun Park, Woong-Yang Park, Doo Ho Choi, Won Park, Won kyung Cho, Nalee Kim
    Breast Cancer Research and Treatment.2021; 189(1): 167.     CrossRef
  • Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02)
    Jae Sik Kim, Kyubo Kim, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Yong Bae Kim, Jee Suk Chang, Doo Ho Choi, Won Park, Tae Hyun Kim, Mison Chun, Jihye Cha, Jin Hee Kim, Dong Soo Lee, Sun Young Lee, Hae Jin Park
    Journal of Breast Cancer.2020; 23(2): 194.     CrossRef
  • Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14)
    Kyubo Kim, Su Ssan Kim, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Doo Ho Choi, Won Park, Sun Young Lee, Mison Chun, Jin Hee Kim, Yong Bae Kim, Jihye Cha, Hae Jin Park, Dong Soo Lee, Wonguen Jung
    Clinical Breast Cancer.2020; 20(1): 51.     CrossRef
  • Combined Therapy Can Improve the Outcomes of Breast Cancer with Isolated Supraclavicular Lymph Node Involvement


    Tianyi Ma, Yan Mao, Haibo Wang
    Cancer Management and Research.2020; Volume 12: 11857.     CrossRef
  • 8,810 View
  • 331 Download
  • 16 Web of Science
  • 13 Crossref
Close layer
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2019;51(3):1041-1051.   Published online November 1, 2018
DOI: https://doi.org/10.4143/crt.2018.424
AbstractAbstract PDFPubReaderePub
Purpose
We compared the oncologic outcomes of breast-conserving surgery plus radiation therapy (BCS+RT) and modified radical mastectomy (MRM) under anthracycline plus taxane-based (AT) regimens and investigated the role of adjuvant radiation therapy (RT) in patients with pathologic N1 (pN1) breast cancer treated by mastectomy.
Materials and Methods
We retrospectively reviewed the medical records of 2,011 patients with pN1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions between January 2006 and December 2010. Two-to-one propensity score matching was performed for balances in variables between the groups.
Results
The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). After propensity score matching, 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were analyzed finally. The overall survival, disease-free survival, locoregional failure-free survival, and regional failure-free survival (RFFS) curves of the BCS+RT group vs. MRM-alone group were not significantly different. The subgroup analysis revealed that in the group with both lymphovascular invasion (LVI) and histologic grade (HG) III, the BCS+RT showed significantly superior RFFS (p=0.008). Lymphedema (p=0.007) and radiation pneumonitis (p=0.031) occurred more frequently in the BCS+RT group than in the MRM-alone group, significantly.
Conclusion
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer. However, BCS+RT group showed superior RFFS to MRM-alone group in the patients with LVI and HG III. Adjuvant RT might be considerable for pN1 breast cancer patients with LVI and HG III.

Citations

Citations to this article as recorded by  
  • Investigation of the clinical benefits of regular breath-holding training utilizing surface guided radiation therapy technology for patients with left breast cancer
    Hongming Li, Zheng Miao, Jie Shen, Jianing Xiao, Zhiwei Yang, Wei Tian, Xiansong Sun, Zhen Zhou, Jing Shen, Jie Qiu
    Journal of Radiation Research and Applied Sciences.2025; 18(2): 101393.     CrossRef
  • 21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery
    Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
    The Breast.2024; 74: 103679.     CrossRef
  • Assessing Radiation Effects on Chemo-Treated BT20 and 4T1 Breast Cancer, and Neuroblastoma Cell Lines: A Study of Single and Multiple-Cell Ionization via Infrared Laser Trapping
    Mulugeta S. Goangul, Daniel B. Erenso, Ying Gao, Li Chen, Kwame O. Eshun, Gisela Alvarez, Horace T. Crogman
    Radiation.2024; 4(1): 85.     CrossRef
  • Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis
    Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter
    BJS Open.2024;[Epub]     CrossRef
  • Radiotherapy dosimetry and radiotherapy related complications of immediate implant-based reconstruction after breast cancer surgery
    Yu Zhang, Fuxiu Ye, Yun Teng, Jin Zheng, Chunlu Li, Ruilan Ma, Haichen Zhang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients
    Gabriel De la Cruz Ku, Manish Karamchandani, Diego Chambergo-Michilot, Alexis R. Narvaez-Rojas, Michael Jonczyk, Fortunato S. Príncipe-Meneses, David Posawatz, Salvatore Nardello, Abhishek Chatterjee
    Annals of Surgical Oncology.2022; 29(10): 6163.     CrossRef
  • Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
    Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
    BMC Cancer.2022;[Epub]     CrossRef
  • Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
    Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Chemo-treated 4T1 breast cancer cells radiation response measured by single and multiple cell ionization using infrared laser trap
    Endris Muhammed, Li Chen, Ying Gao, Daniel Erenso
    Scientific Reports.2019;[Epub]     CrossRef
  • 9,313 View
  • 317 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04)
Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha
Cancer Res Treat. 2018;50(3):964-974.   Published online October 24, 2017
DOI: https://doi.org/10.4143/crt.2017.346
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to assess prognostic value of metastatic pelvic lymph node (mPLN) in early-stage cervical cancer treated with radical surgery followed by postoperative chemoradiotherapy. Also, we sought to define a high-risk group using prognosticators for recurrence.
Materials and Methods
A multicenter retrospective study was conducted using the data from 13 Korean institutions from 2000 to 2010. A total of 249 IB-IIA patients with high-risk factors were included. We evaluated distant metastasis-free survival (DMFS) and disease-free survival (DFS) in relation to clinicopathologic factors including pNstage, number of mPLN, lymph node (LN)ratio (number of positive LN/number of harvested LN), and log odds of mPLNs (log(number of positive LN+0.5/number of negative LN+0.5)).
Results
In univariate analysis, histology (squamous cell carcinoma [SqCC] vs. others), lymphovascular invasion (LVI), number of mPLNs (≤ 3 vs. > 3), LN ratio (≤ 17% vs. > 17%), and log odds of mPLNs (≤ ‒0.58 vs. > ‒0.58) were significant prognosticators for DMFS and DFS. Resection margin involvement only affected DFS. No significant survival difference was observed between pN0 patients and patients with 1-3 mPLNs. Multivariate analysis revealed that mPLN > 3, LVI, and non-SqCC were unfavorable index for both DMFS (p < 0.001, p=0.020, and p=0.031, respectively) and DFS (p < 0.001, p=0.017, and p=0.001, respectively). A scoring system using these three factors predicts risk of recurrence with relatively high concordance index (DMFS, 0.69; DFS, 0.71).
Conclusion
mPLN > 3 in early-stage cervical cancer affects DMFS and DFS. A scoring system using mPLNs > 3, LVI, and non-SqCC could stratify risk groups of recurrence in surgically resected early-stage cervix cancer with high-risk factors.

Citations

Citations to this article as recorded by  
  • Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study
    Yang Wang, Xingyu Liu, Jing Liu, Liying Liu, Yue Ma
    Archives of Gynecology and Obstetrics.2025; 311(1): 123.     CrossRef
  • Current Paradigm and Future Directions in the Management of Nodal Disease in Locally Advanced Cervical Cancer
    Elki Sze-Nga Cheung, Philip Yuguang Wu
    Cancers.2025; 17(2): 202.     CrossRef
  • Spectral computed tomography in the assessment of metastatic lymph nodes in cervical cancer patients treated with definitive radiotherapy: a single-center, prospective study
    Zheng Zeng, Yining Chen, Yuliang Sun, Bing Zhou, Haoran Xu, Lei He, Ke Hu, Jie Qiu, Fuquan Zhang, Junfang Yan
    Clinical & Experimental Metastasis.2025;[Epub]     CrossRef
  • A Hybrid Model-Based Clinicopathological Features and Radiomics Based on Conventional MRI for Predicting Lymph Node Metastasis and DFS in Cervical Cancer
    Mingke Tian, Fengying Qin, Xinyan Sun, Huiting Pang, Tao Yu, Yue Dong
    Journal of Imaging Informatics in Medicine.2025;[Epub]     CrossRef
  • Significance of tumor size and number of positive nodes in patients with FIGO 2018 stage IIIC1 cervical cancer
    Michihide Maeda, Seiji Mabuchi, Mina Sakata, Satoki Deguchi, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shoji Kamiura
    Japanese Journal of Clinical Oncology.2024; 54(2): 146.     CrossRef
  • Internal Validation of Predictive Models for Recurrence-Free Survival and Risk of Recurrence in Patients with Figo Stages I–IV Cervical Cancer
    Jorge Cea García, Francisco Márquez Maraver, M. Carmen Rubio Rodríguez, Laura Ríos-Pena, Inmaculada Rodríguez Jiménez
    Indian Journal of Gynecologic Oncology.2024;[Epub]     CrossRef
  • Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy
    Gui-Fen Ma, Gen-Lai Lin, Si-Tong Wang, Ya-Yu Huang, Chun-Li Xiao, Jing Sun, Ting-Yan Shi, Li-Bing Xiang
    BMC Women's Health.2024;[Epub]     CrossRef
  • Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively
    Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun
    BMC Women's Health.2024;[Epub]     CrossRef
  • Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study
    Yanna Ye, Rui Lian, Zhiqiang Li, Xiaolin Chen, Yahong Huang, Jilong Yao, Anwei Lu, Jinghe Lang, Ping Liu, Chunlin Chen
    BMC Cancer.2024;[Epub]     CrossRef
  • Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023
    Syed S Abrar, Seoparjoo Azmel Mohd Isa, Suhaily Mohd Hairon, Najib M Yaacob, Mohd Pazudin Ismail
    Cureus.2024;[Epub]     CrossRef
  • New Classification of Tumor Microvessels and the Risk of Regional Metastasis in Squamous Cell and Glandular Cancers
    Marina Senchukova
    American Journal of Clinical and Experimental Medicine.2024; 12(5): 61.     CrossRef
  • Analysis of prognostic factors for cervical mucinous adenocarcinoma and establishment and validation a nomogram: a SEER-based study
    Yiping Hao, Qingqing Liu, Ruowen Li, Zhonghao Mao, Nan Jiang, Bingyu Wang, Wenjing Zhang, Baoxia Cui
    Journal of Obstetrics and Gynaecology.2023;[Epub]     CrossRef
  • Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
    Xingtao Long, Misi He, Lingling Yang, Dongling Zou, Dong Wang, Yuemei Chen, Qi Zhou
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Development of novel tracers for sentinel node identification in cervical cancer
    Keisuke Kodama, Chuya Tateishi, Tsuyoshi Oda, Lin Cui, Kazutaka Kuramoto, Hideaki Yahata, Kaoru Okugawa, Shoji Maenohara, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Takeshi Mori, Yoshiki Katayama, Kiyoko Kato
    Cancer Science.2023; 114(11): 4216.     CrossRef
  • Preoperative prediction of cervical cancer survival using a high-resolution MRI-based radiomics nomogram
    Jia Li, Hao Zhou, Xiaofei Lu, Yiren Wang, Haowen Pang, Daniel Cesar, Aiai Liu, Ping Zhou
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Abdominal Radical Hysterectomy as an Alternative Treatment Option for Patients with Cervical Cancer without Access to Radiotherapy Facilities
    Yanna Ye, Zhiqiang Li, Biliang Chen, Shan Kang, Bin Ling, Li Wang, Jilong Yao, Jinghe Lan, Ping Liu, Chunlin Chen
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • Canine anal sac gland carcinoma with regional lymph node metastases treated with sacculectomy and lymphadenectomy: Outcome and possible prognostic factors
    Jean‐Benoit Tanis, Angharad B. Simlett‐Moss, Malgorzata Ossowksa, Thomas W. Maddox, James Guillem, Cristobal Lopez‐Jimenez, Gerry Polton, Rachel Burrow, Riccardo Finotello
    Veterinary and Comparative Oncology.2022; 20(1): 276.     CrossRef
  • The prognostic value of the number of positive lymph nodes and the lymph node ratio in early‐stage cervical cancer
    Ester P. Olthof, Constantijne H. Mom, Malou L. H. Snijders, Hans H. B. Wenzel, Jacobus van der Velden, Maaike A. van der Aa
    Acta Obstetricia et Gynecologica Scandinavica.2022; 101(5): 550.     CrossRef
  • Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis
    Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
    Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas
    Yue Wang, Ruby Jean Chang, Rong-Zhen Luo, Jing Yu, Xiaofei Zhang, Xianghong Yang, M.R. Quddus, Li Li, Wentao Yang, Aijun Liu, Qingping Jiang, Ruijiao Zhao, Huiting Zhu, Feng Zhou, Yiying Wang, Xiujie Sheng, Li-Li Liu, Yan-Lin Wen, Natalie Banet, C.J. Sung
    American Journal of Surgical Pathology.2022; 46(5): 713.     CrossRef
  • Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy
    Seiji Mabuchi, Naoko Komura, Michiko Kodama, Michihide Maeda, Yuri Matsumoto, Shoji Kamiura
    Current Oncology.2022; 29(7): 4856.     CrossRef
  • Development and validation of a nomogram for predicting pelvic lymph node metastasis and prognosis in patients with cervical cancer
    Mengting Wang, Min Ma, Liju Yang, Chengtong Liang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma
    Can Zhang, Xinghua Zhu, Yong Li, Jia Shao, Haibo Xu, Lei Chen, Youli Dan, Hua Jin, Aiqin He
    Medicine.2022; 101(41): e31178.     CrossRef
  • Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer?
    Xiaojuan Lv, Huiting Rao, Tao Feng, Chufan Wu, Hanmei Lou
    Radiation Oncology.2022;[Epub]     CrossRef
  • Prognostic value of lymph node ratio in cervical cancer: A meta-analysis
    Haixia Cui, Yuan Huang, Weibo Wen, Xiangdan Li, Dongyuan Xu, Lan Liu
    Medicine.2022; 101(42): e30745.     CrossRef
  • The Impact of Revised FIGO 2018 Staging System on Survival Outcomes in Patients with Carcinoma Cervix
    Sharanya Sathish, Geeta Acharaya, Kiran Kulkarni, Gayatri Ravikumar
    Indian Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy
    Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
    Yonsei Medical Journal.2021; 62(3): 231.     CrossRef
  • Recurrence pattern and prognostic factors for survival in cervical cancer with lymph node metastasis
    Cigdem Kilic, Gunsu Kimyon Comert, Caner Cakir, Dilek Yuksel, Bahadır Codal, Fatih Kilic, Osman Turkmen, Alper Karalok, Ozlem Moraloglu Tekin, Nurettin Boran, Taner Turan
    Journal of Obstetrics and Gynaecology Research.2021; 47(6): 2175.     CrossRef
  • Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis
    Max Peters, Astrid A.C. de Leeuw, Christel N. Nomden, Kari Tanderup, Kathrin Kirchheiner, Jacob C. Lindegaard, Christian Kirisits, Christine Haie-Meder, Alina Sturdza, Lars Fokdal, Umesh Mahantshetty, Peter Hoskin, Barbara Segedin, Kjersti Bruheim, Bhavan
    Radiotherapy and Oncology.2021; 163: 150.     CrossRef
  • Prognostic Value of Lymph Node Characteristics in Patients with Cervical Cancer Treated with Radical Hysterectomy
    Yoon Hee Lee, Gun Oh Chong, Su Jeong Kim, Ja Hyun Hwang, Jong Mi Kim, Nora Jee-Young Park, Dae Gy Hong
    Cancer Management and Research.2021; Volume 13: 8137.     CrossRef
  • The Combination of T Stage and the Number of Pathologic Lymph Nodes Provides Better Prognostic Discrimination in Early-Stage Cervical Cancer With Lymph Node Involvement
    Yongrui Bai, Ling Rong, Bin Hu, Xiumei Ma, Jiahui Wang, Haiyan Chen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy
    Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan
    Journal of Gynecologic Oncology.2020;[Epub]     CrossRef
  • Predictive value of preoperative serum squamous cell carcinoma antigen (SCC–Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study
    Qinhao Guo, Jun Zhu, Yong Wu, Hao Wen, Lingfang Xia, Xiaohua Wu, Xingzhu Ju
    European Journal of Surgical Oncology.2020; 46(1): 131.     CrossRef
  • Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer——from the large database of 46,313 cases of cervical cancer in China
    Weili Li, Ping Liu, Weidong Zhao, Zhaohong Yin, Zhong Lin, Xiaonong Bin, Jinghe Lang, Chunlin Chen
    European Journal of Surgical Oncology.2020; 46(1): 148.     CrossRef
  • DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer
    Shuhang Qin, Yuandong Liao, Qiqiao Du, Wei Wang, Jiaming Huang, Pan Liu, Chunliang Shang, Tianyu Liu, Meng Xia, Shuzhong Yao
    Cancer Cell International.2020;[Epub]     CrossRef
  • Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?
    Luigi Pedone Anchora, Vittoria Carbone, Valerio Gallotta, Francesco Fanfani, Francesco Cosentino, Luigi Carlo Turco, Camilla Fedele, Nicolò Bizzarri, Giovanni Scambia, Gabriella Ferrandina
    Cancers.2020; 12(6): 1552.     CrossRef
  • UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
    Hideki Matsuoka, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Akihito Horie, Junzo Hamanishi, Tsukasa Baba, Masaki Mandai
    BMC Cancer.2020;[Epub]     CrossRef
  • Validation of the 2018 FIGO Classification for Cervical Cancer: Lymphovascular Space Invasion Should Be Considered in IB1 Stage
    Vincent Balaya, Benedetta Guani, Laurent Magaud, Hélène Bonsang-Kitzis, Charlotte Ngô, Patrice Mathevet, Fabrice Lécuru
    Cancers.2020; 12(12): 3554.     CrossRef
  • Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer
    Giorgio Bogani, Daniele Vinti, Ferdinando Murgia, Valentina Chiappa, Umberto Leone Roberti Maggiore, Fabio Martinelli, Antonino Ditto, Francesco Raspagliesi
    International Journal of Gynecological Cancer.2019; 29(9): 1355.     CrossRef
  • Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer
    P. Widschwendter, W. Janni, C. Scholz, A. De Gregorio, N. De Gregorio, T W P Friedl
    Archives of Gynecology and Obstetrics.2019; 300(6): 1709.     CrossRef
  • Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)
    Maki Matoda, Nobuhiro Takeshima, Hirofumi Michimae, Takashi Iwata, Harushige Yokota, Yutaka Torii, Yorito Yamamoto, Kazuhiro Takehara, Shin Nishio, Hirokuni Takano, Mika Mizuno, Yoshiyuki Takahashi, Yuji Takei, Tetsuya Hasegawa, Mikio Mikami, Takayuki Eno
    Gynecologic Oncology.2018; 149(3): 513.     CrossRef
  • 10,780 View
  • 340 Download
  • 50 Web of Science
  • 42 Crossref
Close layer
Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study
Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon-Joo Kim, Eun Sook Lee, Keun Seok Lee, Han-Sung Kang, In Hae Park, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2017;49(4):970-980.   Published online January 4, 2017
DOI: https://doi.org/10.4143/crt.2016.382
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.
Materials and Methods
We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.
Results
A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.
Conclusion
We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

Citations

Citations to this article as recorded by  
  • Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
    Nalee Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Kyung Hwan Shin, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Yong Bae Kim
    International Journal of Radiation Oncology*Biology*Physics.2025; 121(2): 341.     CrossRef
  • De-escalation of regional nodal irradiation fields in pT1-2N1 breast cancer patients after breast conserving surgery: retrospective real-world clinical experience
    Ji Hyun Hong, Jin-Ho Song, Kyu-Hye Choi, Shin Woo Kim, Woo-Chan Park, Jieun Lee, Ahwon Lee, Jun Kang, Byung-Ock Choi
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
    Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
    Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
    BMC Cancer.2022;[Epub]     CrossRef
  • What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
    Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992.     CrossRef
  • Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation
    Shin-Hyung Park, Jae-Chul Kim
    Radiation Oncology Journal.2020; 38(1): 44.     CrossRef
  • Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era
    Fabio Corsi, Luca Sorrentino, Sara Albasini, Daniela Bossi, Carlo Morasso, Laura Villani, Marta Truffi
    Medicine.2020; 99(35): e21721.     CrossRef
  • Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy
    Xuran Zhao, Yu Tang, Shulian Wang, Yong Yang, Hui Fang, Jianyang Wang, Hao Jing, Jianghu Zhang, Guangyi Sun, Siye Chen, Jing Jin, Yongwen Song, Yueping Liu, Bo Chen, Shunan Qi, Ning Li, Yuan Tang, Ningning Lu, Hua Ren, Yexiong Li
    Radiation Oncology.2020;[Epub]     CrossRef
  • Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
    Haeyoung Kim, Heejung Kim, Won Park, Jong Yun Baek, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Jin Ho Kim, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Jee Suk Chang,
    Cancers.2020; 12(11): 3261.     CrossRef
  • Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
    Jaeho Kim, Won Park, Jin Kim, Doo Choi, Yeon-Joo Kim, Eun Lee, Kyung Shin, Jin Kim, Kyubo Kim, Yong Kim, Sung-Ja Ahn, Jong Lee, Mison Chun, Hyung-Sik Lee, Jung Kim, Jihye Cha
    Cancers.2019; 11(5): 680.     CrossRef
  • Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
    Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
    Cancer Research and Treatment.2018; 50(4): 1316.     CrossRef
  • 10,811 View
  • 319 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)
Yeon-Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2017;49(4):927-936.   Published online December 26, 2016
DOI: https://doi.org/10.4143/crt.2016.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy.
Materials and Methods
We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010.
Results
We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).
Conclusion
PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Citations

Citations to this article as recorded by  
  • Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
    Munaser Alamoodi
    European Journal of Breast Health.2024; 20(2): 81.     CrossRef
  • Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
    Lin-Yu Xia, Wei-Yun Xu, Yan Zhao, Sudeep Gupta
    PLOS ONE.2022; 17(6): e0270528.     CrossRef
  • Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
    Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
    The Breast.2022; 66: 54.     CrossRef
  • Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all
    Majd Kayali, Joseph Abi Jaoude, Arafat Tfayli, Nagi El Saghir, Philip Poortmans, Youssef H. Zeidan
    Critical Reviews in Oncology/Hematology.2020; 147: 102880.     CrossRef
  • The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
    Jinli Wei, Yizhou Jiang, Zhimin Shao
    The Breast.2020; 51: 40.     CrossRef
  • The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
    Lei Zhang, Ru Tang, Jia-Peng Deng, Wen-Wen Zhang, Huan-Xin Lin, San-Gang Wu, Zhen-Yu He
    BMC Cancer.2020;[Epub]     CrossRef
  • Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
    Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
    Cancer Research and Treatment.2019; 51(3): 1041.     CrossRef
  • Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
    Jie Zhang, Xiao-Xiao Wang, Jun-Yu Lian, Chuan-Gui Song
    Oncotarget.2019; 10(50): 5245.     CrossRef
  • Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
    Shin-Hyung Park, Jeeyeon Lee, Jeong Eun Lee, Min Kyu Kang, Mi Young Kim, Ho Yong Park, Jin Hyang Jung, Yee Soo Chae, Soo Jung Lee, Jae-Chul Kim
    Radiation Oncology Journal.2018; 36(4): 285.     CrossRef
  • 11,445 View
  • 346 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Erratum
ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy
Min Kyu Kang, Dongryul Oh, Kwan Ho Cho, Sung Ho Moon, Hong-Gyun Wu, Dae-Seog Heo, Yong Chan Ahn, Keunchil Park, Hyo Jung Park, Jun Su Park, Ki Chang Keum, Jihye Cha, Jun Won Kim, Yeon-Sil Kim, Jin Hyoung Kang, Young-Taek Oh, Ji-Yoon Kim, Sung Hwan Kim, Jin-Hee Kim, Chang Geol Lee
Cancer Res Treat. 2016;48(1):425-425.   Published online January 10, 2016
DOI: https://doi.org/10.4143/crt.2014.141.2
Corrects: Cancer Res Treat 2015;47(4):871
PDFPubReaderePub
  • 9,513 View
  • 91 Download
  • 1 Web of Science
Close layer
Original Articles
The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Cho, Chul Seung Kay, Yeon-Sil Kim
Cancer Res Treat. 2016;48(3):917-927.   Published online December 28, 2015
DOI: https://doi.org/10.4143/crt.2015.265
AbstractAbstract PDFPubReaderePub
Purpose
We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). Materials and Methods A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed.
Results
After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). Conclusion This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.

Citations

Citations to this article as recorded by  
  • Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma
    Yihong Lin, Xiongbin Yu, Linbin Lu, Hong Chen, Junxian Wu, Yaying Chen, Qin Lin, Xuewen Wang, Xi Chen, Xiong Chen
    Cancer Biomarkers.2023; 37(1): 1.     CrossRef
  • Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis
    Shan-Shan Yang, Jian-Gui Guo, Jia-Ni Liu, Zhi-Qiao Liu, En-Ni Chen, Chun-Yan Chen, Pu-Yun OuYang, Fei Han, Fang-Yun Xie
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies
    Minmin Li, Bin Zhang, Qiuying Chen, Lu Zhang, Xiaokai Mo, Zhuozhi Chen, Zhe Jin, Luyan Chen, Jingjing You, Shuixing Zhang
    Head & Neck.2021; 43(6): 1912.     CrossRef
  • Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion Weighted Imaging in Evaluating the Radio-sensitivity of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy
    Youping Xiao, Ying Chen, Yunbin Chen, Zhuangzhen He, Yiqi Yao, Jianji Pan
    Cancer Research and Treatment.2019; 51(1): 345.     CrossRef
  • Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management
    Yong Chan Ahn
    Radiation Oncology Journal.2019; 37(2): 67.     CrossRef
  • A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma
    Pu-Yun OuYang, Xiao-Min Zhang, Xing-Sheng Qiu, Zhi-Qiao Liu, Lixia Lu, Yuan-Hong Gao, Fang-Yun Xie
    The Oncologist.2019; 24(4): 505.     CrossRef
  • Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis
    Teng Hwee Tan, Yu Yang Soon, Timothy Cheo, Francis Ho, Lea Choung Wong, Jeremy Tey, Ivan W.K. Tham
    Radiotherapy and Oncology.2018; 129(1): 10.     CrossRef
  • Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
    Jiraporn Setakornnukul, Kullathorn Thephamongkhol
    BMC Cancer.2018;[Epub]     CrossRef
  • TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series
    N. Toumi, W. Ben Kridis, W. Mnejja, R. Bouzguenda, A. Khanfir, A. Ghorbel, J. Daoud, M. Frikha
    Cancer/Radiothérapie.2018; 22(3): 216.     CrossRef
  • Does concurrent chemoradiotherapy preceded by chemotherapy improve survival in locally advanced nasopharyngeal cancer patients? Experience from Ghana
    Joel Yarney, Naa A. Aryeetey, Alice Mensah, Emmanuel D. Kitcher, Verna Vanderpuye, Charles Aidoo, Kenneth Baidoo
    Cancers of the Head & Neck.2017;[Epub]     CrossRef
  • Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
    Mei Lan, Chunyan Chen, Ying Huang, Li Tian, Zhijun Duan, Fei Han, Junfang Liao, Meiling Deng, Terence T. Sio, Anussara Prayongrat, Lie Zheng, Shaoxiong Wu, Taixiang Lu
    Scientific Reports.2017;[Epub]     CrossRef
  • A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
    H. M. Li, P. Li, Y. J. Qian, X. Wu, L. Xie, F. Wang, H. Zhang, L. Liu
    BMC Cancer.2016;[Epub]     CrossRef
  • 13,408 View
  • 150 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
Mee Sun Yoon, Seung Jae Huh, Hak Jae Kim, Young Seok Kim, Yong Bae Kim, Joo-Young Kim, Jong-Hoon Lee, Hun Jung Kim, Jihye Cha, Jin Hee Kim, Juree Kim, Won Sup Yoon, Jin Hwa Choi, Mison Chun, Youngmin Choi, Kang Kyoo Lee, Myungsoo Kim, Jae-Uk Jeong, Sei Kyung Chang, Won Park
Cancer Res Treat. 2016;48(3):1074-1083.   Published online October 29, 2015
DOI: https://doi.org/10.4143/crt.2015.356
AbstractAbstract PDFPubReaderePub
Purpose
We evaluated the role of adjuvant therapy in stage IIIA endometrioid adenocarcinoma patients who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy (CTRT) according to risk group. Materials and Methods A multicenter retrospective study was conducted including patients with surgical stage IIIA endometrial cancertreated by radical surgery and adjuvant RT or CTRT. Disease-free survival (DFS) and overall survival (OS) were analyzed.
Results
Ninety-three patients with stage IIIA disease were identified. Nineteen patients (20.4%) experienced recurrence, mostly distant metastasis (17.2%). Combined CTRT did not affect DFS (74.1% vs. 82.4%, p=0.130) or OS (96.3% vs. 91.9%, p=0.262) in stage IIIA disease compared with RT alone. Patients with age ≥ 60 years, grade G2/3, and lymphovascular space involvement had a significantly worse DFS and those variables were defined as risk factors. The high-risk group showed a significant reduction in 5-year DFS (≥ 2 risk factors) (49.0% vs. 88.0%, p < 0.001) compared with the low-risk group (< 2). Multivariate analysis confirmed that more than one risk factor was the only predictor of worse DFS (hazard ratio, 5.45; 95% confidence interval, 2.12 to 13.98; p < 0.001). Of patients with no risk factors, a subset treated with RT alone showed an excellent 5-year DFS and OS (93.8% and 100%, respectively). Conclusion We identified a low-risk subset of stage IIIA endometrioid adenocarcinoma patients who might be reasonable candidates for adjuvant RT alone. Further randomized studies are needed to determine which subset might benefit from combined CTRT.

Citations

Citations to this article as recorded by  
  • Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer
    Jessica Jou, Lindsey Charo, Marianne Hom-Tedla, Katherine Coakley, Pratibha Binder, Cheryl Saenz, Ramez N. Eskander, Michael McHale, Steven Plaxe
    Gynecologic Oncology.2021; 163(2): 299.     CrossRef
  • Treatment strategies for endometrial cancer: current practice and perspective
    Yeh C. Lee, Stephanie Lheureux, Amit M. Oza
    Current Opinion in Obstetrics & Gynecology.2017; 29(1): 47.     CrossRef
  • 14,419 View
  • 126 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy
Min Kyu Kang, Dongryul Oh, Kwan Ho Cho, Sung Ho Moon, Hong-Gyun Wu, Dae-Seog Heo, Yong Chan Ahn, Keunchil Park, Hyo Jung Park, Jun Su Park, Ki Chang Keum, Jihye Cha, Jun Won Kim, Yeon-Sil Kim, Jin Hyoung Kang, Young-Taek Oh, Ji-Yoon Kim, Sung Hwan Kim, Jin-Hee Kim, Chang Geol Lee
Cancer Res Treat. 2015;47(4):871-878.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.141
Correction in: Cancer Res Treat 2016;48(1):425
AbstractAbstract PDFPubReaderePub
Purpose
To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. Materials and Methods From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy).
Results
Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last followup, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. Conclusion Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.

Citations

Citations to this article as recorded by  
  • Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study
    Fang Wang, Lu Zhou, Li-Jun Zhang, Chang-Bin Xie, Zhi-Wei Liao, Xiao-Dan Lin, Yue-Feng Wen
    Radiotherapy and Oncology.2024; 191: 110081.     CrossRef
  • A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
    Yao-Can Xu, Kai-Hua Chen, Zhong-Guo Liang, Xiao-Dong Zhu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma
    Yang Liu, Jianghu Zhang, Jingbo Wang, Runye Wu, Xiaodong Huang, Kai Wang, Yuan Qu, Xuesong Chen, Yexiong Li, Ye Zhang, Junlin Yi
    Radiology and Oncology.2022; 56(4): 479.     CrossRef
  • The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma
    Xin-Bin Pan, Ling Li, Song Qu, Long Chen, Shi-Xiong Liang, Xiao-Dong Zhu
    Oral Oncology.2020; 101: 104520.     CrossRef
  • Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study
    Di‐Han Liu, Xiao‐Yu Zhou, You‐Guang Pan, Si Chen, Zheng‐Hao Ye, Gang‐Dong Chen
    Cancer Medicine.2020; 9(4): 1287.     CrossRef
  • Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update
    Ting Jin, Qun Zhang, Dong-Hua Luo, Feng Jiang, Qi-Feng Jin, Yuan-Yuan Chen, Xiao-Zhong Chen, Wei-Min Mao
    Translational Oncology.2020; 13(1): 25.     CrossRef
  • Predictive factors of chemotherapy use in stage II nasopharyngeal carcinoma
    Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Xiao-Dong Zhu
    Medicine.2019; 98(7): e14512.     CrossRef
  • The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database
    Zaheer Ahmed, Lara Kujtan, Kevin Kennedy, Valerie Wood, David Schomas, Janakiraman Subramanian
    Cancer Medicine.2019; 8(4): 1500.     CrossRef
  • Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study
    Xue-Song Sun, Di-Han Liu, Sai-Lan Liu, Qiu-Yan Chen, Shan-Shan Guo, Yue-Feng Wen, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Xiao-Yun Li, Jin-Jie Yan, Ming-Huang Hong, Jun Ma, Lin-Quan Tang, Hai-Qiang Mai
    Cancer Research and Treatment.2019; 51(4): 1449.     CrossRef
  • Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature
    Sufang Wang, Shan Li, Liangfang Shen
    Current Problems in Cancer.2018; 42(3): 302.     CrossRef
  • The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era
    Pei-Jing Li, Hao-Yuan Mo, Dong-Hua Luo, Wei-Han Hu, Ting Jin
    Oral Oncology.2018; 85: 95.     CrossRef
  • Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy
    Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Jia-Lin Ma, Song Qu, Ling Li, Long Chen, Xiao-Dong Zhu
    Oncotarget.2017; 8(8): 14029.     CrossRef
  • Chemotherapy use and survival in stage II nasopharyngeal carcinoma
    Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Xiao-Dong Zhu
    Oncotarget.2017; 8(60): 102573.     CrossRef
  • Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era
    Qiaojuan Guo, Tianzhu Lu, Shaojun Lin, Jingfeng Zong, Zhuhong Chen, Xiaofei Cui, Yu Zhang, Jianji Pan
    Japanese Journal of Clinical Oncology.2016; 46(3): 241.     CrossRef
  • Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma
    Kai-Hua Chen, Xiao-Dong Zhu, Ling Li, Song Qu, Zhen-Qiang Liang, Xia Liang, Xin-Bin Pan, Zhong-Guo Liang, Yan-Ming Jiang
    Oncotarget.2016; 7(42): 69041.     CrossRef
  • Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
    Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng, Pu-Yun OuYang, Fang-Yun Xie
    Oncotarget.2015; 6(41): 44019.     CrossRef
  • 14,265 View
  • 104 Download
  • 23 Web of Science
  • 16 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP